FITC Anti-Vaccinia Virus 抗体 (ab19970)
Key features and details
- FITC Rabbit polyclonal to Vaccinia Virus
- Suitable for: ICC/IF
- Reacts with: Vaccinia virus
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG
製品の概要
-
製品名
FITC Anti-Vaccinia Virus antibody
Vaccinia Virus 一次抗体 製品一覧 -
製品の詳細
FITC Rabbit polyclonal to Vaccinia Virus -
由来種
Rabbit -
標識
FITC. Ex: 493nm, Em: 528nm -
特異性
Ab19970 recognizes purified virions. -
アプリケーション
適用あり: ICC/IFmore details -
種交差性
交差種: Vaccinia virus -
免疫原
Tissue, cells or virus corresponding to Vaccinia Virus. Lister strain (mixture of virions and infected cell polypeptides)
-
特記事項
IgG fraction covalently coupled with high purity Isomer I of fluorescein isothiocyanate.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C. -
バッファー
Preservative: 0.1% Sodium azide
Constituents: 0.0268% PBS, 1% BSA -
Concentration information loading...
-
精製度
Protein A purified -
特記事項(精製)
Care is taken to ensure complete removal of any free fluorescein from the final product. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab19970の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
ICC/IF |
Use at an assay dependent dilution.
|
特記事項 |
---|
ICC/IF
Use at an assay dependent dilution. |
ターゲット情報
-
関連性
Vaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize vaccinia virus infection and enable identification other viral and cellular proteins which participate in the vaccinia virus entry process. -
別名
- Orthopoxvirus antibody
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (4)
ab19970 は 4 報の論文で使用されています。
- Chen W et al. Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. Oncol Rep 41:67-76 (2019). PubMed: 30365143
- Lauron EJ et al. Viral MHCI inhibition evades tissue-resident memory T cell formation and responses. J Exp Med 216:117-132 (2019). PubMed: 30559127
- Hou W et al. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. Int J Cancer 135:1238-46 (2014). PubMed: 24474587
- Li Z et al. A flow cytometry-based immuno-titration assay for rapid and accurate titer determination of modified vaccinia Ankara virus vectors. J Virol Methods 169:87-94 (2010). PubMed: 20637240